3D Interaction,drug ligand name,target,Uniprot code,n_ca_T,n_ca_M,n_local_pairs,local_rmsd,local_coverage,vendor,smiles,clinical_phase,moa,database,cids,target chain id,chain name,Align Length,Binding_Affinity_kcal/mol
3NYN_SGV_Q6PLK2.pdb,SGV,3NYN,Q6PLK2,553,446,196,0.624,0.439,Toronto,NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12,Phase 1,DNA inhibitor,Uniprot,14978,A,protein kinase B-like protein [Plasmodium falciparum],270,-7.109
3NYN_SGV_O77239.pdb,SGV,3NYN,O77239,553,305,112,0.659,0.367,Toronto,NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12,Phase 1,DNA inhibitor,Uniprot,14978,A,cdk-related protein kinase 6 [Plasmodium falciparum],302,-7.645
4TNB_SGV_Q6PLK2.pdb,SGV,4TNB,Q6PLK2,529,446,169,0.677,0.379,Toronto,NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12,Phase 1,DNA inhibitor,Uniprot,14978,A,protein kinase B-like protein [Plasmodium falciparum],270,-7.056
